| Q35889846 | A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers |
| Q91163028 | A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index |
| Q37960202 | Advancements in the use of blood tests for cancer screening in women at high risk for endometrial and breast cancer |
| Q82674463 | All by itself |
| Q42089905 | Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. |
| Q50607650 | Approaches to the detection of ovarian cancer. |
| Q36595049 | Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome |
| Q35832948 | Autoantibodies to mesothelin in infertility |
| Q37322280 | Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels |
| Q34627880 | B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression |
| Q37324630 | Bead-based ELISA for validation of ovarian cancer early detection markers |
| Q24651567 | Beyond CA125: the coming of age of ovarian cancer biomarkers |
| Q37346072 | Biomarker discovery in ovarian cancer. |
| Q38087982 | Biomarkers for early detection of ovarian cancer |
| Q57790341 | Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study |
| Q24170226 | CA125 expression in spontaneous ovarian adenocarcinomas from laying hens |
| Q50544475 | CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. |
| Q79790234 | CA125: megadaltons of novel opportunities |
| Q36773181 | CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma |
| Q35067887 | CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. |
| Q34134506 | CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy |
| Q37611453 | Claudin and ovarian cancer |
| Q33484414 | Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer |
| Q36304002 | Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients |
| Q35204609 | Clinically relevant microRNAs in ovarian cancer |
| Q39281993 | Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance |
| Q36090095 | Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer |
| Q53555568 | Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. |
| Q37324647 | Combining a symptoms index with CA 125 to improve detection of ovarian cancer. |
| Q83319304 | Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia |
| Q36400522 | Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women |
| Q47124965 | Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City |
| Q30440200 | Comprehensive analysis of HE4 expression in normal and malignant human tissues |
| Q90431091 | Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis |
| Q36996793 | Contemporary progress in ovarian cancer screening |
| Q36686826 | Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer |
| Q37730502 | Correlation of cytohistlogical expression and serum level of ca125 in ovarian neoplasm |
| Q40277231 | Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells |
| Q35100951 | Current state of biomarker development for clinical application in epithelial ovarian cancer |
| Q36560848 | Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6. |
| Q34412873 | Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers |
| Q47593475 | Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review |
| Q50608736 | Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. |
| Q90227045 | Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer |
| Q37154456 | Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system |
| Q34797749 | Differential hRad17 expression by histologic subtype of ovarian cancer. |
| Q57941761 | Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma |
| Q37460195 | Early Detection of Cancer: Immunoassays for Plasma Tumor Markers |
| Q34094731 | Early detection of ovarian cancer |
| Q37076713 | Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer |
| Q90682389 | Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives |
| Q47336919 | Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass |
| Q51874223 | Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. |
| Q51603232 | Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. |
| Q24634978 | HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases |
| Q83694304 | HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma |
| Q41588744 | HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population |
| Q51091632 | HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. |
| Q83970096 | HE4: a new potential early biomarker for the recurrence of ovarian cancer |
| Q24658024 | High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma |
| Q84934387 | Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system |
| Q28248479 | Human kallikrein 10, a predictive marker for breast cancer |
| Q42276827 | Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets |
| Q84427641 | Identification of novel epithelial ovarian cancer biomarkers by cross-laboratory microarray analysis |
| Q44508865 | Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications |
| Q55297626 | Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach. |
| Q55249100 | Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer. |
| Q88644473 | Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients |
| Q37270601 | Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. |
| Q37865952 | Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma? |
| Q35758403 | Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. |
| Q28478285 | Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody |
| Q33441919 | Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas |
| Q37154428 | Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers |
| Q37967486 | Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form. |
| Q35760160 | Molecular approaches to personalizing management of ovarian cancer |
| Q36627755 | Molecular biomarkers for cancer detection in blood and bodily fluids |
| Q48005561 | Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant |
| Q53286689 | More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. |
| Q36816028 | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
| Q34994831 | Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice |
| Q35298842 | Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. |
| Q64890083 | Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. |
| Q36054395 | Ovarian cancer biomarkers: current options and future promise |
| Q33702218 | Ovarian cancer immunotherapy: opportunities, progresses and challenges |
| Q39421659 | Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening |
| Q57941661 | Ovarian cancer specific kallikrein profile in effusions |
| Q36556482 | Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers |
| Q33941562 | Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells |
| Q33651139 | Pathogenesis of ovarian cancer: clues from selected overexpressed genes |
| Q35922723 | Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. |
| Q37760524 | Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. |
| Q51356061 | Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. |
| Q37340624 | Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash |
| Q51351089 | Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. |
| Q28078658 | Precision targeted therapy of ovarian cancer |
| Q51559029 | Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. |
| Q37249395 | Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer |
| Q36528900 | Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer |
| Q33944027 | Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer |
| Q36296331 | Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II. |
| Q90195272 | Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer |
| Q93532917 | Reply: The performance of the risk of ovarian malignancy algorithm |
| Q38723616 | Risk factors for Barrett's esophagus: a scoping review |
| Q83976174 | Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer |
| Q47960574 | Role of osteopontin in differential diagnosis of ovarian tumors |
| Q43557526 | Screening for ovarian cancer: imaging challenges and opportunities for improvement. |
| Q36001438 | Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing |
| Q33983058 | Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study |
| Q39388741 | Serum HE4 as a diagnostic and prognostic marker for lung cancer |
| Q53411263 | Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. |
| Q82407168 | Serum carbonic anhydrase IX during first-line therapy of ovarian cancer |
| Q36808757 | Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. |
| Q36752512 | Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response |
| Q37799046 | Status of tumor markers in epithelial ovarian cancer has there been any progress? A review |
| Q33553922 | TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients |
| Q35663610 | The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors |
| Q51607181 | The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? |
| Q21198791 | The detection, treatment, and biology of epithelial ovarian cancer |
| Q37096960 | The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial |
| Q35185032 | The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. |
| Q37952006 | The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). |
| Q38100999 | The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. |
| Q35112866 | The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis |
| Q61854359 | The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass |
| Q41592587 | Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement |
| Q37789033 | Tumor markers for early detection of ovarian cancer |
| Q90289065 | Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors |
| Q43195485 | Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer |
| Q49057114 | Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer |
| Q36029907 | Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment |
| Q33653799 | Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. |
| Q36823332 | Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery |
| Q37348306 | Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. |
| Q37026450 | Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer |
| Q36414088 | Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer |
| Q21284411 | WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung |
| Q38530989 | Why have ovarian cancer mortality rates declined? Part III. Prospects for the future |
| Q35021181 | fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma |